Nereus Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1998-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nereuspharm.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- Nereus Pharmaceuticals, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT00630110
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸San Diego Pacific Oncology & Hematology Associates, Encinitas, California, United States
🇺🇸University San Diego Moores Cancer Center, San Diego, California, United States
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- Nereus Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00322608
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
News
No news found